For Immediate Release

**Empamore by Morepen: Revolutionizing Diabetes Care with Affordable, High-Quality Treatment**

Gurugram, India – March 17, 2025: Morepen Laboratories Limited announces the launch of **Empamore**, a game-changing **treatment for Type 2 Diabetes** Mellitus (T2DM), **Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD)**. With India being the **diabetes capital of the world** and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.

**Empamore: More Safety, More Efficacy, More Affordability**

Morepen **manufactures Empagliflozin (API)** in its **USFDA-approved facilities** and already has European DMF. The launch of Empamore reflects Morepen’s **40 years** of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality. The product range includes:

* Empagliflozin (Empamore 10mg/25mg)
* Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)

Empagliflozin is a globally recognized SGLT2 inhibitor, widely used for diabetes management. With pre-diabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9%, Morepen’s launch of Empamore comes at a crucial time to provide an affordable and effective solution.

**Bridging the Healthcare Gap with Affordable Access**

Speaking on the launch, **Ashutosh Sharma, V.P. - Sales & Marketing**, Morepen Laboratories, said:

“*At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain. This aligns with our commitment to empower people to take charge of their health.”*

**Competitive Pricing & Nationwide Availability**

The market price of Empagliflozin tablets has historically been high, making it inaccessible for many. With Morepen’s launch of Empamore at a fraction of the cost, the company aims to capture a significant share of the rapidly growing diabetes market in India, ensuring that quality treatment is no longer a privilege but a right for every patient.

**Morepen’s Legacy in Diabetes Care**

Morepen has been a pioneer in diabetes management solutions, having installed **over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips**. Empamore is a natural extension of Morepen’s commitment to empowering people with “Health in Your Hands”, offering them the tools they need to prevent, monitor, and treat diabetes effectively.

**Empamore: Redefining Patient-Centric Diabetes Care**

* Unmatched Affordability: Priced significantly lower than leading brands, ensuring access for all.
* Comprehensive Diabetes Solution: Beyond glycemic control, it addresses cardiovascular and renal complications.
* Global Quality Standards: Manufactured at Morepen’s USFDA-approved plant with DMF-grade quality, ensuring top-tier safety and efficacy.
* Innovative Packaging: Designed with perforated strip packaging for convenience and adherence, making daily management easier for patients.

**Serving India & The World**

With an extensive global footprint spanning 82 countries, Morepen continues to raise the bar in pharmaceutical innovation. The launch of Empamore reflects the company’s dedication to bringing affordable healthcare solutions to millions, not just in India but worldwide.

**About Morepen Laboratories Ltd.**

Morepen Laboratories, established in 1984, is a leading player in the pharmaceutical and healthcare industry. With a strong presence in APIs, medical devices, and finished formulations, Morepen has consistently demonstrated innovation and market leadership. The company is a global leader in exporting 6 key API products, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine.

In the medical devices segment, Morepen has made remarkable strides in Point of Care (POC) diagnostics, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, driving expansion into tier-2 and tier-3 cities.

For more details, visit [www.morepen.com](http://www.morepen.com).

Media Contact:

Morepen Laboratories Ltd.
Corporate Office: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar – III, Sector 20, Gurugram, Haryana – 122016
Email: corporate@morepen.com
Nitika Saini, Manager – Corporate Communication | +91 9818533004

Forward-Looking Statements:

This press release contains forward-looking statements based on current expectations and assumptions regarding anticipated developments and other factors affecting the company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.